anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The widespread and increasing use of nanomaterials has resulted in a higher likelihood of exposure by inhalation for nanotechnology workers. However, tracking the internal dose of nanoparticles deposited at the airways level, is still challenging. To assess the suitability of particle number concentration determination as biomarker of internal dose, we carried out a cross sectional investigation involving 80 workers handling nanomaterials. External exposure was characterized by portable counters of particles DISCminiTM (Testo, DE), allowing to categorize 51 workers as exposed and 29 as non-exposed (NE) to nanoparticles. Each subject filled in a questionnaire reporting working practices and health status. Exhaled breath condensate was collected and analysed for the number of particles/ml as well as for inflammatory biomarkers. A clear-cut relationship between the number of airborne particles in the nano-size range determined by the particle counters and the particle concentration in exhaled breath condensate (EBC) was apparent. Moreover, inflammatory cytokines (IL-1β, IL-10, and TNF-α) measured in EBC, were significantly higher in the exposed subjects as compared to not exposed. Finally, significant correlations were found between external exposure, the number concentration of particles measured by the nanoparticle tracking analysis (NTA) and inflammatory cytokines. As a whole, the present study, suggests that NTA can be regarded as a reliable tool to assess the inhaled dose of particles and that this dose can effectively elicit inflammatory effects.
PURPOSE: To obtain a mucin having solubility and bacterial adherence inhibitory activity, useful for foods, cosmetics, medicines, etc., by demulsifying a waste liquor resulted from washing or boiling pig internal organs to eliminate the fat contained, concentrating the water-soluble fraction followed by protease treatment to recover the decomposed product. CONSTITUTION: A waste liquor resulted from washing or boiling mucin-contg. pig internal organs (e.g. stomach) is incorporated with 0.5-5wt.% of a demulsifier (e.g. potassium chloride) followed by treatment at 50-60 deg.C under a pressure of 150kg/cm<2> to effect demulsifying the liquor, and the resultant liquor is continuously centrifuged by using a continuous ultra centrifuge and separated into an aqueous solution layer and a fat layer. The aqueous solution layer is then recovered and the resultant mucin-contg. water-soluble fraction is subjected to membrane treatment using a precision filtration membrane 0.1-0.3μm in average pore size to be concentrated.  Next, the concentrated fraction is subjected to protease treatment (e.g. with trypsin) to oligomerize the mucin, and the water-soluble fraction containing the mucin thus oligomerized is concentrated through an ultrafiltration membrane 100-300kDa in fractionating molecular weight, thus obtaining the objective mucin.
Patients who are 60 years old or older for laparoscopic abdominal surgery will be randomly assigned into two groups: 1) sevoflurane-based general anesthesia group, and 2) propofol-based general anesthesia group. Each group will need 221 patients to detect 1/3 of decrease or increase in the rate of POCD of one group compared with another group at about one week after surgery, assuming the overall rate of POCD at this time is about 40% at this time. Considering about 10% loss to follow-up, we will have 250 patients in each group. In addition, investigators will need 184 subjects in the control group. The data of these control subjects will be used to normalize the data of the two studied groups to diagnose POCD. The subjects in control groups will also be elderly but without the exposure to anesthesia and surgery.
Decades of investigation demonstrate that hepatic encephalopathy (HE), a common complication of cirrhosis characterized by impaired cognition, develops as a consequence of intestinal microbial products reaching the brain. Recent investigation has found that cirrhotic patients, especially those who have developed HE, have intestinal dysbiosis compared to normal controls. Several plausible mechanisms explain how intestinal dysbiosis could lead to HE. There is limited prior literature on the efficacy of FMT in cirrhosis. The largest documented study of 10 cirrhotic patients receiving a single FMT enema found no significant change in microbiome diversity as assessed by 16S rRNA sequencing. The investigators hypothesize that aggressive manipulation of the microbial composition with fecal microbiota transplant (FMT) will improve neurological function in patients with a history of cirrhosis and HE. The investigators additionally hypothesize that five oral FMT capsule administrations from a previously efficacious stool donor will significantly change the intestinal microbiome composition of a cirrhotic patient. The study will consist of a 10-patient open-label pilot study to identify efficacious stool donors, defined as donors who precipitate the largest improvement in recipient neurological function and microbiome composition. The two most efficacious pilot study stool donors will be selected to donate stool for the randomized controlled trial (RCT). The 20-patient RCT will investigate the effect of FMT on neurological outcomes in patients with cirrhosis and a history of HE. Subjects will be randomized to receive 5 doses of oral FMT capsules or placebo capsules over 21 days. Cognitive testing and stool collections will occur at 4 time points, to assess for changes in neurological function and microbiome composition. The primary outcome is change in neurological function after FMT. The main secondary outcome is change in microbiome composition after FMT. This study could provide valuable information about the ability of FMT to improve intestinal dysbiosis in cirrhosis and treat HE.
INTRODUCTION: Thoracic aorta false aneurysms (TAFA) are unexplored complications after cardiac surgery associated with significant morbidity and mortality. Therefore, the purpose of this study was to examine the clinical profiles, surgical techniques, and operative outcomes, of patients treated for TAFA at a single institution.
METHODS: From 1996 to 2022, 112 patients were treated for aortic pseudoaneurysm (mean age 55 ± 14 years, 78 patients were male). In the majority of the patients (90%) TAFA developed after previous cardiovascular surgery, the most common diagnosis and surgical procedure preceding the TAFA development was an aortic dissection (52%) and Bentall procedure (47%). In the rest of the cohort, the leading cause was trauma.
RESULTS: Sixty-one percent of patients were indicated for reintervention (surgical reoperation, endoluminal graft implantation, septal occluder implantation, coil embolization, or a combination of procedures). Overall, 52 patients had undergone cardiac reoperation. TAFA was resected and the aorta was repaired in 55% or replaced in 45%. Operative mortality was 5.7%. In postoperative follow-up, a hypoechogenic lesion encircling aortic prosthesis was present in 94%, therefore it was determined as a negative prognostic factor. The mean follow-up was 13.2 ± 19.4 years.
CONCLUSION: Although there is no specific approach how to prevent TAFA development, maintaining normal blood pressure and regular follow-up should be applied. More frequent follow-ups should be performed in patients with a hypoechogenic lesion encircling and aortic prosthesis. Early detection during long-term postoperative follow-up, an individually tailored approach of a multidisciplinary team is necessary for favorable treatment outcomes.
<P>PROBLEM TO BE SOLVED: To provide a good agent for improving a bowel movement and improving skin that is prepared from adlay.  <P>SOLUTION: A ground product of adlay with husks is treated with alpha amylase and protease and then with transglucosidase. The obtained material is dried without being filtered and then powdered to adlay decomposed with enzymes. The agent for improving a bowel movement contains the adlay decomposed with enzymes. The adlay decomposed with enzymes is also used as an agent for easing a lower back pain, a premenstrual syndrome (PMS), swelling or the like and an agent for improving nail and skin and easing a wart or a pimple.  <P>COPYRIGHT: (C)2010,JPO&INPIT
PURPOSE:To obtain the titled agent effective for the prevention and remedy of mycosis, by using a thioflavone derivative as an active component. CONSTITUTION:The objective agent contains the thioflavone derivative of formula I (R1 and R2 are H, halogen, alkyl, OH or alkoxy; n is 1 or 2) as a main component. The compound of formula I exhibits remarkable growth-inhibiting activity against the pathogenic fungi such as Tricophyton rubrum, Candida albicans, etc., and has an antibacterial activity comparable to or higher than that of the undecylenic acid. The compound of formula I can be prepared in high yield, by dissolving the thioflavone derivative of formula II (obtained by the condensation of a benzenethiol compound and an ethyl benzoylacetate derivative in the presence of a polyphosphoric acid) in a solvent (e.g. acetic acid), and heating in the presence of an oxidizing agent (e.g. excess hydrogen peroxide).
PURPOSE: To obtain an excessive collagen destruction inhibitor contg. 12a- deoxytetracycline, having superior anticollagenase activity and useful for the treatment of articular diseases.  
     CONSTITUTION: An inhibitor contains a compd. of formula [where X 1  is H or dimethylamino; X 2  is H or forms a double bond with C in the 3-position; X 3  and X 4  are each hydroxyl or oxo; the broken lines indicate that C-C bonds or bonds formed by X 1 -X 4  and ring forming C atoms may exist; R 1  is H or -N(CH 3 ) 2 ; and R 2  is H or forms a double bond with C in the 4-position] or its salt, e.g. 4-dedimethylamino-12a-deoxytetracycline. The inhibitor can pharmaceutically be prepared by a conventional method into an administering form such as oral, subcutaneous, transcutaneous, intramuscular, intra-articular or spraying form or a suppository. The dosage of the compd. of the formula to an adult for one day is 1-1,000 mg in the case of oral administration or injection. In the case of external application, a compsn. contg. 0.001-10% of the compd. is applied. The compd. has little toxicity, a side reaction and can be used over a long period of time. 
     COPYRIGHT: (C)1994,JPO
ABSTRACT OF THE INVENTION      A method for achieving elevated circulating plasmin levels and thus causing the dissolution of blood clots is disclosed.          This  method  is  particularly  suited  for  the  treatment  of myocardial infarctions and other clotting disorders. This method involves in two phases the elevation of endogenous, circulating tissue  plasminogen  activator   (tPA)   levels  through  the administration of basic placenta angiogenic factor (PAF).  In the first phase, a relatively high circulating concentration of basic PAF effects the release of tPA from sites in the vascular bed into the circulation.  In the second phase, lower circulating concentrations are maintained for a period of time necessary to induce the synthesis and secretion of tPA.  This induction will elevate the circulating concentrations of tPA,  thus causing increases in the circulating levels of plasmin, an enzyme capable of dissolving blood clots.  A method for accomplishing similar purposes is also disclosed which involves the administration of basic PAF in conjunction with heparin as the active ingredients in a pharmaceutical preparation.
This observational, longitudinal study will recruit approximately 255 patients through the Wake Forest National Cancer Institute Community Oncology Research Program (NCORP) Research Base (WF NCORP RB). The recruitment goal will be to have 160 participants who complete the interviewer-administered Structured Questionnaire at all three time points. All participants will be administered the first Structured Questionnaire prior to a prostatectomy or initiation of radiation therapy to treat adenocarcinoma of the prostate. Participants will also be administered Structured Questionnaires at three and six months after the prostatectomy or completion of radiation therapy. For most patients, the time between study enrollment and completion of participation will be approximately 6 - 10 months. Interviewer-administered Structured Questionnaires will address work ability, job characteristics, presence of symptoms associated with adenocarcinoma of the prostate treatment, and general background information.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to psychotherapy, reflexotherapy, physiotherapy. Method includes carrying out bioresonance testing (BRT) of functional state by means of hardware-software complex Vitatest. After that, with patient in lying on back position, transcranial electrostimulation (TES) and trance guidance at the background of aromatherapy and relaxation music for 20-25 minutes. After that, painful zones on hands and feet are detected and reflexotherapeutic impact is performed on detected zones until pain disappears. Further impact is performed depending on detected during BRT disorders. In case of dominating asthenic-depressive manifestations impact is performed in accordance with Su Jok correspondence system on points and zones of brain projection of anti-depressive direction, located on pads of distal feet phalanxes, reflexotherapy of corporal points VC14 jujue 1.5 cun lower than xiphoid precess of sternum, on the middle line of abdomen, anti-depressive herbal drugs with are administered for one month from beginning of cycles of procedures. In case of asthenic and vegetative-vascular manifestations rexlexotherapy is performed on points of heart projections on palms and little toes, on corporal points C4, C9 with administration of stimulating medications - bioadaptogens for 1-2 months. In case of anxiety and phobic disorders, R1 points are stimulated with intake of sedative phytopreparations for 1-3 months. In case of chronic fatigue impact is performed on corporal points TR1, point and deep massage of cervical-collar zone is performed and course of neuroprotectors - essential amino acids is administered for 1 to 3 months symptoms disappear completely. In case of post-trauma stress disorder, reflexotherapeutic impact is performed on the 1-st, 6-th and 11-th days in corporal points IG-8, J-17by sedative method, on the 2-nd, 7-th, 14-th day in points F-8, J-4, R-12 - by tonic method with intake of allopathic and homeopathic preparation with sedative action for 1-3 months.EFFECT: method reduces treatment terms with increase of remission duration from 10 months to one year.5 ex
The invention relates to a preparation method of a fungus secondary metabolite spiropreussione A and an application thereof in preparing antibiotics and antitumor drugs, belonging to the technology field of chemical and biological engineering. The invention provides a liquid fermentation process of spiropreussione A-producing Preussia sp. strain AS-5; a method for preparing the spiropreussione A from the AS-5 mycelia and the fermentation liquid; the structure and physical and chemical properties of the compound; and an inhibitor activity of the compound on Staphylococcus aureus and tumor cells. The inventive preparation method has the advantages of high growth speed of Preussia sp. strain AS-5, simple fermentation process, and low production cost. The secondary metabolite spiropreussione A from the AS-5 strain has the advantages of novel structure, high content in the fermentation product, and simple preparation method.
Placebo is in capsule form and contains an inactive substance. It is taken by mouth once a night, approximately 30 minutes prior to bed for 6 months.
Arm 1 patients will receive CARA breast support. The known benefits to using CARA for breast positioning are reduction in IMF skin folds during treatment, reduction in breast separation, and reduction in V50% body, V105% body and lung V20 Gy in treatment planning. No known risks to using CARA have been identified.
Hypoxia is a prevalent characteristic of numerous neurological disorders including stroke, Alzheimer's disease, and Parkinson's disease. Extracellular vesicles (EVs) are minute particles released by cells that contain diverse biological materials, including proteins, lipids, and nucleic acids. They have been implicated in a range of physiological and pathological processes including intercellular communication, immune responses, and disease progression. EVs are believed to play a pivotal role in modulating the microenvironment of hypoxia-associated neurological diseases. These EVs are capable of transporting hypoxia-inducible factors such as proteins and microRNAs to neighboring or remote cells, thereby influencing their behavior. Furthermore, EVs can traverse the blood-brain barrier, shielding the brain from detrimental substances in the bloodstream. This enables them to deliver their payload directly to the brain cells, potentially intensifying the effects of hypoxia. Nonetheless, the capacity of EVs to breach the blood-brain barrier presents new opportunities for drug delivery. The objective of this study was to elucidate the role of EVs as mediators of information exchange during tissue hypoxia, a pathophysiological process in ischemic stroke and malignant gliomas. We also investigated their involvement in the progression and regression of major diseases of the central nervous system, which are pertinent to the development of therapeutic interventions for neurological disorders.
The repositioning of maxillary segment is essential for esthetic and functional outcomes in orthognathic surgery. With the giant leap in three-dimensional (3D) computer-aided surgical simulation (CASS) technology development, surgeons are now able to simulate various surgical plans in a computer to achieve the best possible outcome. In order to transfer the virtual surgical plan to the patient at the time of the surgery, surgical splints manufactured by computer-aided design and manufacturing (CAD/CAM) technique has been traditionally used to intraoperative reposition the maxilla. Nonetheless, the position of maxilla is still dependent to mandibular autorotation. The instability of the mandibular condyle-fossa relationship is a potential problem that may directly affect the placement of the maxillary segment at the desired position. Personalized titanium plates manufactured using titanium 3D printing technique have been used for maxilla repositioning and fixation to improve the operative accuracy in orthognathic surgery. Despite this, the evidence for advantage of this personalized titanium plates technique is not very strong and based on only a few studies.

The purpose of this study is to determine whether personalized titanium plates can achieve better accuracy than CAD/CAM surgical splint in maxilla repositioning in orthognathic surgery. The accuracy of using both methods for maxilla repositioning was quantitatively evaluated using linear and angular measurement. Secondary outcomes include operative time, amount of intraoperative blood loss, preoperative preparation time and treatment cost will also be measured to evaluate the feasibility of clinical application of personalized titanium plates technique in orthognathic surgery.
Placebo group participants will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, vitamin C: 0 mg); continous administration of placebo product for 12 weeks.
Frailty is a geriatric syndrome linked to adverse outcomes. Co-occurring cardiometabolic factors increase frailty risk; however, their distinct combinations (typologies) associated with frailty are unclear. We aimed to identify subgroups of older adults with distinct cardiometabolic typologies and characterize their relationship with structural determinants and frailty to inform tailored approaches to prevent and delay frailty. This study was cross-sectional design and included 7984 community-dwelling older adults (65+ years) enrolled in the Health and Retirement Study (2006 and 2008). Latent class analysis was performed using seven cardiometabolic indicators (abdominal obesity, obesity, low high-density lipoprotein; and elevated blood pressure, blood sugar, total cholesterol, C-reactive protein). Frailty was indicated by ≥3 features (weakness, slowness, fatigue, low physical activity, unintentional weight loss). Logistic regression was used to examine the relationship between structural determinants (gender, race/ethnicity, and education), cardiometabolic typologies, and frailty. Three cardiometabolic subgroups were identified: insulin-resistant (n = 3547), hypertensive dyslipidemia (n = 1246), and hypertensive (n = 3191). Insulin-resistant subgroup members were more likely to be female, non-Hispanic Black, and college non-graduates; hypertensive dyslipidemia subgroup members were more likely to be non-Hispanic Others and report high school education; and hypertensive subgroup members were more likely to be male and college educated (p≤.05). Frailty risk was higher for females, Hispanic or Non-Hispanic Black older adults, and those with lower education (p≤.001). Frailty risk was greater in the insulin-resistant compared to the other subgroups (both aOR=2.0, both p<.001). Findings highlight a need to design tailored interventions targeting cardiometabolic typologies to prevent and delay frailty.
PURPOSE:To obtain a medicated cosmetic, capable of maintaining gaseous carbon dioxide at a high concentration for a long period and having high sustaining effects on promotion of blood circulation by containing the gaseous carbon dioxide in water using a specific water-soluble nonionic polymer. CONSTITUTION:A medicated cosmetic containing (A) 0.01-20wt.%, preferably 0.1-10wt.% water-soluble nonionic polymer having heterocyclic rings in the molecule, e.g. cellulosic derivatives, natural polysaccharides or synthetic polymers, especially hydroxyethyl cellulose having 200-2000 polymerization degree, (B) 0.01-10wt.%, preferably 1-5wt.% gaseous carbon dioxide and further, as necessary, (C) 0.1-30wt.%, preferably 0.5-20wt.% surfactant. The ingredient (C) is blended to provide a foamy cosmetic. Thereby, holding effects on gaseous carbon dioxide are further improved. The gaseous carbon dioxide is preferably blended in an amount so as to provide 4-8kg/cm<2> pressure in filling thereof in a pressure-resistant container and >=500ppm gas concentration of the cosmetic just after jetting and >=400ppm gas concentration thereof after 10min.
1,191,530. Keratolytic compositions. DERMAL LABORATORIES Ltd. 4 Oct., 1968 [4 Oct., 1967], No. 45139/67. Heading A5B. A keratolytic composition comprises a cellfree, neomycin-free lycphilisate of a culture of streptomyces fradial IMI 61202 (active ingredient apparently the enzyme keratinase) dispersed in an anhydrous carrier. Preferably the carrier is an emulsifying ointment base or a polyethylene glycol, the lyophilisate preferably being 0.5-5% by weight of the composition. Cla(OH) 2  in an amount so as to bring, in an equal weight of water the pH to 8.5-10 may be present. In use, the compositions are preferalbly mixed with water in a ratio composition: water of 1:2-2:1. The active ingredient may be prepared by removal of the cells from a culture of streptomyces fradial IMI 61202 (e.g. by filtration), followed by removal of neomycin by contacting with a cationic exchange resin and then with activated charcoal. The material is then lyophilised by evaporation at 0.20‹C. and under high vacuum.